This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Hentig, N.
Right arrow Articles by Lötsch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Hentig, N.
Right arrow Articles by Lötsch, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2273-2275, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01565-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen{triangledown}

Nils von Hentig,1* Pavel Kaykhin,2 Christoph Stephan,2 Errol Babacan,2 Martin Stürmer,3 Schlomo Staszewski,2 and Jörn Lötsch1

Pharmazentrum Frankfurt, Institute of Clinical Pharmacology,1 HIVCENTER, Medical Clinics II,2 Institute of Medical Virology at the Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany3

Received 5 December 2007/ Returned for modification 23 February 2008/ Accepted 5 April 2008

The human immunodeficiency virus protease inhibitor combination of atazanavir (ATV)-lopinavir-ritonavir was reported to exhibit a mutual pharmacoenhancement of plasma lopinavir and ATV concentrations which may be beneficial for salvage patients. We identified 17 patients in our pharmacokinetic database taking this combination and found conflicting results. Plasma concentrations of both ATV and lopinavir were modestly, although not significantly, decreased when the drugs were coadministered. Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised.

* Corresponding author. Mailing address: Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Phone: 49-69-63016956. Fax: 49-69-63017636. E-mail: Hentig{at}em.uni-frankfurt.de

{triangledown} Published ahead of print on 14 April 2008.

Antimicrobial Agents and Chemotherapy, June 2008, p. 2273-2275, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01565-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»